Simon Baker

In some markets, that's up to 2% of the population. So I just wonder if you could give us an idea on your thoughts of the size of that opportunity

I just wonder if you could give us some of your feedback on the patient and physician experience and reaction to Yeztugo

when you are expecting to see a potential benefit, as the lower cost of patients increases starts and increases stay time

should we assume that the entirety is SPIKE vax? And also, Jamie, I wonder if you could give us any comments on phasing

You mentioned the spend on respiratory trials being 50%. Was that 50% of your total trial spend or 50% of your R&D spend

I just wonder what the scope of your ambition was in that setting, given the role of T cell infiltration in glaucoma